JACKSON, Miss.- Mississippi will receive over half a million dollars from a $35 million settlement after Pfizer Inc. apparently improperly marketed its drug Rapamune.
Mississippi and 41 other states are involved in the settlement with Pfizer, the parent company of Wyeth Pharmaceuticals Inc. The deal resolves allegations Wyeth misrepresented the uses of the drug Rapamune.
Mississippi Attorney General Jim Hood told WAPT, “state consumer protection laws were violated by misrepresentation of the uses and benefits of Rapamune.”
Rapamune was approved by the Food and Drug Administration to help prevent the rejection of kidney transplants. The states said Pfizer unit Wyeth Pharmaceuticals Inc. promoted the drug for other uses that weren’t approved by the regulator.
New York-based Pfizer said in a statement the alleged activity occurred d before it acquired Wyeth. Pfizer didn’t admit wrongdoing or liability as part of the settlement.
Mississippi will receive a total of $532,675 from the settlement.